Results 1 to 1 of 1
Page 1 of 1
A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)
Journal of Clinical Oncology
Yau, TCC; Sukeepaisarnjaroen, W; Chao, Y; Yen, CJ; Lausoontornsiri, W; Chen, PJ; Sanpajit, T; Lencioni, R; Camp, A; Kallender, H; Ottesen, LH; Poon, RTP2011256
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download